Product
Bleomycin
Aliases
Blanoxan, Blenoxane, Blenoxane®, Bleo, BLEO (3 other aliases)
26 clinical trials
30 indications
Indication
Hodgkin lymphomaIndication
Venous MalformationIndication
lymphomaIndication
Hodgkin Lymphoma, Ann Arbor Stage IIBIndication
Hodgkin LymphomaIndication
Hodgkin Lymphoma, Ann Arbor Stage IVAIndication
Stage IVB Hodgkin LymphomaIndication
Hodgkin lymphoma in childrenIndication
Vascular MalformationsIndication
Stage I Hodgkin LymphomaIndication
Hodgkin lymphoma, Ann Arbor stage IBIndication
Hodgkin Lymphoma Stage IIIndication
Lymphocyte-Rich Classic Hodgkin LymphomaIndication
Germ Cell TumorIndication
TeratomaIndication
Testicular Germ Cell TumorIndication
lymphatic malformationIndication
Metastatic CancerIndication
HemangiomaIndication
PropranololIndication
Germ Cell TumorsIndication
Chemotherapy-induced toxicityIndication
Cardiovascular MorbidityIndication
Ovarian Germ Cell CancerIndication
Ovarian CancerIndication
Ovarian Sex Cord Stromal TumorClinical trial
Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)Status: Active (not recruiting), Estimated PCD: 2023-10-11
Clinical trial
Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous MalformationsStatus: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL).Status: Active (not recruiting), Estimated PCD: 2021-11-02
Clinical trial
Phase I/II of Nivolumab and A(B)VD in the Front-line Setting for High Risk Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Protocol H8 for a Prospective Controlled Trial in Clinical Stage I-II Supradiaphragmatic Hodgkin's Disease. Evaluation of Treatment Efficacy and (Long Term) Toxicity in Three Different Prognostic Subgroups [H8 Trial]Status: , Estimated PCD: 1998-10-01
Clinical trial
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young AdultsStatus: Active (not recruiting), Estimated PCD: 2021-12-31
Clinical trial
Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin LymphomaStatus: Completed, Estimated PCD: 2015-05-01
Clinical trial
Trattamento Delle Malformazioni Venose a Basso Flusso Con l'Elettroscleroterapia. Studio Osservazionale ProspetticoStatus: Recruiting, Estimated PCD: 2026-11-28
Clinical trial
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
Prospective Controlled Trial in Clinical Stages I-II Supradiaphragmatic Hodgkin's Disease: Evaluation of Treatment Efficacy, (Long Term) Toxicity and Quality of Life in Two Different Prognostic SubgroupsStatus: , Estimated PCD: 2004-05-01
Clinical trial
BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's LymphomaStatus: , Estimated PCD: 2010-01-01
Clinical trial
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)Status: Active (not recruiting), Estimated PCD: 2024-09-23
Clinical trial
HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADDStatus: Active (not recruiting), Estimated PCD: 2022-12-01
Clinical trial
Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's DiseaseStatus: , Estimated PCD: 2000-05-01
Clinical trial
A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell TumorsStatus: Active (not recruiting), Estimated PCD: 2012-03-29
Clinical trial
Efficacy and Safety of Different Concentrations of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric PatientsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients With Newly Diagnosed, Advanced Hodgkin LymphomaStatus: Completed, Estimated PCD: 2016-01-31
Clinical trial
A PROSPECTIVE RANDOMIZED TRIAL OF BLEOMYCIN VS. DOXYCYCLINE VS. TALC FOR THE INTRAPLEURAL TREATMENT OF MALIGNANT PLEURAL EFFUSIONSStatus: , Estimated PCD: 2003-02-01
Clinical trial
Role of Propranolol as Compared to Bleomycin in Management of HemangiomaStatus: Completed, Estimated PCD: 2017-05-09
Clinical trial
Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-Risk Germ Cell TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL)Status: Terminated, Estimated PCD: 2015-04-09
Clinical trial
Investigating Cardiovascular Adverse Events Related to Cancer Treatment: a Study of Extreme Toxicity Using Induced Pluripotent Stem CellsStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2030-09-01
Clinical trial
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's DiseaseStatus: Completed, Estimated PCD: 2011-09-01
Clinical trial
A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Malignant Ovarian Germ Cell TumorsStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Ovarian Malignant Sex Cord-Stromal TumorsStatus: Recruiting, Estimated PCD: 2025-05-01